BIOASTER collaborates with Bio-Rad and Genetic Analysis to develop novel microbiome-based diagnostics within the field of metabolic disorders
Resulting new tests will help researchers investigate links between gut microbiota and diabetes and obesity
BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced the initiation of a collaborative program with BIOASTER, Bio-Rad Laboratories, Inc. and Genetic Analysis aimed at evaluating microbial dysbiosis signatures in the field of metabolic disorders.
This project is a unique opportunity for BIOASTER to capitalize on its breakthrough deep and 16S-targeted sequencing technologies and advanced pipelines of data analysis for highlighting new gut microbiome biomarkers of medical added value.
Endocrine and metabolic diseases are among the most common contemporary human afflictions in western countries and particularly in the United States. The high prevalence and incidence of common metabolic disorders such as diabetes and obesity have been confirmed through large population-based studies. Moreover, an increasing number of studies show that deregulation of gut microbiota composition (“dysbiosis”) is associated with onset of metabolic diseases and may impact treatment.
This original collaboration between Bio-Rad, a world leading provider of life science research and clinical diagnostic products, Genetic Analysis, a Norwegian company renowned in microbiome molecular diagnostics and BIOASTER will add an innovative edge of this research program by examining gut microbiota signatures for diagnostics. Genetic Analysis and Bio-Rad previously announced in December 2017 a supply and distributionagreementforGeneti
“This collaborative program illustrates very well BIOASTER’s ambition:
“We are delighted to collaborate with BIOASTER and Bio-Rad on this important research
For more information:
t:+44 7711 821527
BIOASTER is an independent non-profit organisation and one of the 8 French Technological Research Institutes (TRI). It was created in 2012 thanks to the joint efforts of the Paris Institut Pasteur and the Lyonbiopôle competitive cluster.
These original founders were joined at the start by the CEA, the CNRS, INSERM, Danone Nutricia Research, Institut Mérieux and Sanofi Pasteur and later in 2018 by bioMérieux. BIOASTER also benefits from the support of the French government through the Programme Investissements d’Avenir (Investing for the Future program,PIA),of Région Auvergne-Rhône- Alpes and Métropole du Grand Lyon.
In the field of microbiology, BIOASTER develops and implements technological and transformative innovations,which speed up the development of new publichealth solutions and personalised medicine solutions.
BIOASTER is involved in four main application fields:
-Antimicrobials: to identify new medical candidates, to fight antimicrobials resistance
-Vaccines: to improve vaccines safety and efficacy
-Microbiota: to take full advantage of human and animal microbiota
-Diagnostic: to quickly diagnose infections at patient bedside
In each of these fields,our goal is to turn industrial needs into research projects dedicated to solutions and leveraging discoveries from academic research. BIOASTER thus develops a collaborative, multi-disciplinary and technologically integrated approach, to promote open innovation.